|
|
|
|
|
|
by oksurewhynot
570 days ago
|
|
|
I thought this was known about older GLP-1 antagonists like semaglutide, which is why there's some excitement around the newer dual-action types like tirzepatide? My understanding is the newer drugs cause substantially less muscle mass loss. |
|
|